Amgen Inc (AMGN) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$375.65

Open

$376.42

Day range

$374.46 – $379.11

Volume

2.4M

About Amgen Inc

Latest AMGN news

• Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.
  Yahoo Finance · Sep 13, 2026

  Amgen Inc. (AMGN) experienced a significant decline in its stock price, falling over 10% following the disappointing results of a late-stage cardiovascular trial conducted by Novartis. The trial's failure raised alarms about the viability of Amgen's own olpasiran program, which targets lipoprotein(a) or Lp(a), a key risk factor for cardiovascular diseases. The stock closed at $393, reflecting investor concerns about the broader implications for the Lp(a) market and Amgen's pipeline. The setback at Novartis not only affects its own prospects but also casts a shadow over Amgen's strategy in the cardiovascular space. As pharmaceutical companies race to replenish their drug pipelines, negative trial outcomes can lead to increased volatility across the sector. Investors are now questioning the potential for olpasiran to succeed in a competitive market, especially as other companies may also be reevaluating their Lp(a) programs in light of these results. This uncertainty could lead to further stock fluctuations for Amgen and its peers as they navigate the implications of this trial failure.

• Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca
  Yahoo Finance · Sep 11, 2026

  Amgen Inc. and AstraZeneca PLC have received a significant boost in their market positions following promising results from a Phase III clinical trial of their lung cancer therapies. The study demonstrated that the combination of Amgen's Imdelltra (tarlatamab) and AstraZeneca's Imfinzi markedly improved overall survival rates in patients with extensive-stage small-cell lung cancer. This positive outcome not only reinforces the efficacy of both drugs but also enhances their potential for broader market acceptance and use in oncology. Following the announcement, Amgen's stock rose to $391.65, reflecting investor optimism about the future of its targeted immunotherapy. The positive data could lead to increased sales projections for both companies, particularly as they navigate a competitive landscape in cancer treatment. Analysts suggest that successful integration of these therapies could position Amgen and AstraZeneca favorably against other players in the oncology market, potentially driving further investment and collaboration opportunities. As the healthcare sector continues to prioritize innovative treatments, this development underscores the growing importance of combination therapies in improving patient outcomes.

• PE Weekly: M&A Roundup Sept. 4-10
  IPO & M&A · Sep 10, 2026

  The week of September 4-10 saw a flurry of mergers and acquisitions activity, signaling a continued robust interest in consolidation across various sectors. Notably, several high-profile deals were announced, including a significant acquisition in the technology sector, where a major software company agreed to purchase a smaller rival for $2.5 billion. This move is expected to enhance the acquirer's market position and expand its product offerings, reflecting a broader trend of strategic acquisitions aimed at bolstering competitive advantages. In the healthcare sector, a prominent pharmaceutical company announced a merger with a biotech firm specializing in rare diseases, valued at approximately $1.8 billion. This transaction highlights the ongoing trend of larger firms seeking to diversify their portfolios and tap into innovative therapies, which could lead to increased market share and improved R&D capabilities. Analysts suggest that such deals may also attract investor interest, as they often signal growth potential and a commitment to advancing healthcare solutions. Market implications of this M&A activity are significant, as they can lead to shifts in stock valuations and investor sentiment. The heightened deal-making environment may indicate a favorable economic outlook, encouraging companies to pursue growth through acquisitions. However, potential regulatory scrutiny remains a concern, particularly for larger transactions, which could impact deal timelines and valuations. Overall, the M&A landscape appears vibrant, with companies actively seeking opportunities to enhance their strategic positions in an increasingly competitive market.

• Steady stream of crossover rounds stock biotech’s IPO pipeline
  IPO & M&A · Sep 9, 2026

  The biotechnology sector is experiencing a resurgence in initial public offerings (IPOs), driven by a steady influx of crossover funding rounds that have bolstered investor confidence. In recent months, public investors have shown renewed interest in biotech firms, paving the way for a series of anticipated public debuts. This renewed enthusiasm is reflected in the increasing number of companies successfully securing crossover investments, which typically involve both private and public investors, thereby enhancing their market readiness. The implications for the market are significant, as a robust IPO pipeline can attract further investment into the biotech sector, potentially leading to a more favorable environment for innovation and development. As companies prepare for their public offerings, the influx of capital from crossover rounds not only strengthens their financial positions but also signals to other investors that there is a viable path to profitability in the sector. This trend may encourage additional firms to pursue IPOs, further stimulating market activity and possibly leading to a competitive landscape that benefits both investors and consumers through accelerated advancements in biotechnology.

• The benefits of next-generation peptides will be thinly spread
  FT Companies · Sep 9, 2026

  Next-generation peptides, which have garnered attention for their potential in various therapeutic applications, are likely to face challenges in widespread adoption due to their cost and consumer price sensitivity. A recent survey indicates that pricing is a significant factor influencing consumer decisions, with many opting to discontinue use when faced with rising costs. This trend suggests that while the scientific advancements in peptide technology may be promising, their market penetration could be limited if manufacturers do not address affordability. The implications for the peptide market are considerable. As companies strive to innovate and differentiate their products, they may need to balance the costs of research and development with the price points that consumers are willing to accept. If manufacturers cannot find a way to produce these next-generation peptides at a lower cost, the benefits of their advancements may be "thinly spread" across a limited consumer base. This could lead to a fragmented market where only a few players succeed, while others struggle to maintain profitability in a price-sensitive environment. Investors and stakeholders should monitor how pricing strategies evolve in response to consumer behavior, as this will be crucial for the future of peptide therapeutics.

• There are some tremendous healthcare companies in bull market mode, says Jim Cramer
  Market Outlook · Sep 8, 2026

  Jim Cramer, the host of CNBC's "Mad Money," has highlighted a selection of healthcare companies that are currently thriving in what he describes as a bull market. Cramer emphasized that while artificial intelligence continues to capture headlines, investors should not overlook the robust performance and potential of healthcare stocks. He pointed to several firms that are not only showing strong earnings but also exhibiting resilience amid broader market fluctuations. Cramer’s analysis suggests that the healthcare sector is well-positioned for growth, driven by factors such as an aging population, increasing demand for innovative treatments, and advancements in biotechnology. This positive outlook could lead to increased investment in these companies, potentially boosting stock prices and attracting institutional interest. As investors seek to diversify their portfolios beyond tech-driven stocks, Cramer’s insights may encourage a shift towards healthcare, which could further enhance the sector's momentum in the coming months.

• Enhanced FDA-SEC Collaboration: How Life Sciences Companies Think About Disclosure, Insider Trading, and Prediction Markets
  Financial Regulation · Sep 8, 2026

  On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) announced a new Memorandum of Understanding (MOU) aimed at enhancing collaboration between the two agencies. This initiative is expected to significantly impact how life sciences companies approach disclosure practices, insider trading, and prediction markets. By fostering a more integrated regulatory environment, the agencies aim to improve the transparency and accuracy of information provided to investors regarding drug approvals and clinical trial results. The MOU signals a proactive stance by regulators to address the complexities of the life sciences sector, where timely and accurate disclosures are critical for investor decision-making. As the FDA continues to evaluate new therapies and treatments, the SEC's involvement will likely lead to stricter scrutiny of disclosures related to clinical outcomes and potential market-moving events. This heightened oversight could deter insider trading and promote fairer market practices, as companies will need to ensure compliance with both agencies' standards. Market implications are substantial, as enhanced regulatory scrutiny may lead to increased volatility in life sciences stocks, particularly around key FDA announcements. Companies will need to adopt more rigorous disclosure protocols to mitigate risks associated with non-compliance. Investors should prepare for a landscape where information asymmetry is reduced, potentially leading to more informed trading strategies and a shift in how market participants assess the value of biotech and pharmaceutical firms.

• Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
  MarketWatch · Sep 8, 2026

  Shares of Novartis plummeted over 3% on Monday following the disappointing results of a pivotal trial for its cholesterol drug, which aimed to lower lipoprotein(a) or Lp(a) levels to reduce cardiovascular risks. The failure of this trial not only undermines Novartis's strategy but also raises concerns about the broader viability of Lp(a) targeting therapies in the biopharmaceutical sector. Investors had anticipated significant advancements in this area, making the trial results particularly impactful. The fallout from Novartis's announcement extended beyond its own stock, triggering a selloff across the biopharma industry as market participants reevaluated the potential of similar treatments from other companies. The collective market response reflects a growing skepticism towards the efficacy of Lp(a) lowering strategies, which had garnered considerable attention and investment. Analysts suggest that this could lead to a reevaluation of research and development priorities within the sector, as companies may now face increased pressure to demonstrate the viability of their cardiovascular drug pipelines.

• Dow Jones, S&P 500 futures indicate gap-down open while Nasdaq set for flat start; Novartis, Amgen, others to watch
  Futures Trading · Sep 8, 2026

  U.S. stock futures indicate a mixed opening for Wall Street, with Dow Jones and S&P 500 futures suggesting a gap-down start, while Nasdaq futures are poised for a flat opening. This divergence comes as investors digest a complex mix of geopolitical developments and economic indicators. The market is particularly focused on inflation data, with July's Consumer Price Index (CPI) expected to show a modest monthly increase of 0.1% for headline inflation and 0.2% for core inflation, according to Dow Jones economists. The anticipation of these inflation figures is heightened as they could influence the Federal Reserve's monetary policy decisions. A lower-than-expected CPI could bolster hopes for a pause in interest rate hikes, providing support to equities. Conversely, any surprises in the data could lead to volatility, particularly in interest-sensitive sectors. Additionally, market participants are looking ahead to the July Producer Price Index (PPI) set to release on Thursday and retail sales data on Friday, which may further shape economic outlooks. In corporate news, investors will be keeping a close eye on major pharmaceutical companies like Novartis and Amgen, as their earnings reports could impact sector performance and overall market sentiment. As the week unfolds, traders will be balancing these corporate earnings with macroeconomic indicators, which will be crucial in determining market direction amid ongoing geopolitical tensions.

• AI will help find cure for cancer ‘within our lifetimes’, says Arm Holdings chief
  Guardian Business · Sep 8, 2026

  Arm Holdings CEO Rene Haas has expressed optimism that advancements in artificial intelligence (AI) could lead to significant breakthroughs in cancer treatment within the next few decades. Speaking at a recent industry conference, Haas highlighted the potential of AI to analyze vast datasets, identify patterns, and accelerate drug discovery processes, which could ultimately result in more effective therapies for various cancer types. This assertion comes at a time when the intersection of technology and healthcare is garnering increased attention from investors and researchers alike. The integration of AI in medical research not only promises to enhance the efficiency of clinical trials but also to personalize treatment options for patients. As companies like Arm, which specializes in semiconductor technology, continue to innovate, the implications for the biotech sector are profound. Investors may see opportunities in firms that leverage AI to develop new treatments, potentially reshaping the landscape of cancer care. Market analysts are closely watching developments in this area, as the successful application of AI in oncology could lead to significant financial returns for tech and pharmaceutical companies alike. As the healthcare industry increasingly embraces digital transformation, the collaboration between AI firms and biotech companies may pave the way for groundbreaking advancements, making the prospect of curing cancer more attainable than ever before.

All 38 articles in the app →

Index membership

• Dow Jones Industrial Average · Health Care
• S&P 500 · Health Care
• Nasdaq-100 · Health Care

Related Health Care stocks

• JNJJohnson & Johnson
• MRKMerck
• UNHUnitedHealth Group